Occupy Wall Street protester finds occupation on Wall Street — thanks to indie B-D

Occupy Wall Street protester finds occupation on Wall Street — thanks to indie B-D
John Thomas Financial spots, then hires unemployed Ph.D; 'ask me for my resume'
APR 26, 2012
An independent broker-dealer has taken a flyer on an Occupy Wall Street protester. John Thomas Financial hired Tracy Postert, an unemployed Ph.D. in biomedical science, as an assistant to its chief market analyst, Wayne Kaufman. Ms. Postert, who specializes in pharmacology, got the job after Mr. Kaufman spotted her in October in front of the ragtag throng in the now famous Zuccotti Park in Manhattan's financial district. At the time, Ms. Postert was holding a handwritten sign that read: “Ph.D. Biomedical Scientist seeking full-time employment.” The back of the sign read: “Ask me for my resume.” On Oct. 22, Mr. Kaufman did exactly that, and followed up the next day with an e-mail asking Ms. Postert to come in for an interview at John Thomas, an independent broker-dealer with more than 200 brokers. The B-D focuses on raising cash for startups and private deals. Ms. Postert had joined the anti-Wall Street movement in October, and spent two weeks washing sidewalks and making sandwiches at Zuccotti Park, just two blocks from John Thomas' offices at 14 Wall St., according to the New York Post, which first reported the story on Monday. Mr. Kauffman said he was “fascinated” by the Occupy Wall Street movement, and had been making quick visits two or three times a week since the protest began in September to see what was happening at the park. The move to hire Ms. Postert is an effort to build up John Thomas' biotech business, he said. “I typically hire people out of business school,” Mr. Kaufman told InvestmentNews today. “They have MBAs and all that stuff.” Ms. Postert, who is studying for her Series 7 exam, is a markedly different type of candidate, he noted. While she lacks experience in reading financial statements, Ms. Postert has the scientific expertise that can help uncover companies producing potentially winning drugs, Mr. Kaufman said. “We've bought a [biotech] stock at $3 per share, it went to $5 per share, and then we sold it. But the stock [eventually] went to $15 per share, and we didn't fully understand it,” he said. “She will help us understand what's going on at early stage companies and ride them to big winners.” Ms. Postert started at the firm Nov. 15. She says that she has been consistently underemployed since 1999 when she earned her Ph.D. in biomedical science with a specialization in pharmacology. Her last job was in the spring, said Ms. Postert, who declined to give her specific age but said she was in her thirties. “I really like my [new] job, and that's not a BS statement,” said Ms. Postert in an interview this afternoon. “I'm learning to evaluate companies on a financial basis, but I'm not there yet." She is focusing on stocks of biotech companies that create drugs for disease such as hepatitis C and cancer, as well as the extra-cellular matrix, which she describes as the connective “goo” outside of animal cells. “Where I have an edge is with these up-and-coming biotech stocks,” Ms. Postert said. “If a company gets the science right, I'm going to like that company.”

Latest News

SEC bars ex-broker who sold clients phony private equity fund
SEC bars ex-broker who sold clients phony private equity fund

Rajesh Markan earlier this year pleaded guilty to one count of criminal fraud related to his sale of fake investments to 10 clients totaling $2.9 million.

The key to attracting and retaining the next generation of advisors? Client-focused training
The key to attracting and retaining the next generation of advisors? Client-focused training

From building trust to steering through emotions and responding to client challenges, new advisors need human skills to shape the future of the advice industry.

Chuck Roberts, ex-star at Stifel, barred from the securities industry
Chuck Roberts, ex-star at Stifel, barred from the securities industry

"The outcome is correct, but it's disappointing that FINRA had ample opportunity to investigate the merits of clients' allegations in these claims, including the testimony in the three investor arbitrations with hearings," Jeff Erez, a plaintiff's attorney representing a large portion of the Stifel clients, said.

SEC to weigh ‘innovation exception’ tied to crypto, Atkins says
SEC to weigh ‘innovation exception’ tied to crypto, Atkins says

Chair also praised the passage of stablecoin legislation this week.

Brooklyn-based Maridea snaps up former LPL affiliate to expand in the Midwest
Brooklyn-based Maridea snaps up former LPL affiliate to expand in the Midwest

Maridea Wealth Management's deal in Chicago, Illinois is its first after securing a strategic investment in April.

SPONSORED How advisors can build for high-net-worth complexity

Orion's Tom Wilson on delivering coordinated, high-touch service in a world where returns alone no longer set you apart.

SPONSORED RILAs bring stability, growth during volatile markets

Barely a decade old, registered index-linked annuities have quickly surged in popularity, thanks to their unique blend of protection and growth potential—an appealing option for investors looking to chart a steadier course through today's choppy market waters, says Myles Lambert, Brighthouse Financial.